Heartflow, Inc. Form 4 Filings

Heartflow, Inc. (HTFL) reported that its Chief Financial Officer, Vikram Verghese, sold shares of common stock in two open-market transactions made under a Rule 10b5-1 trading plan adopted on June 4, 2026. On September 17, 2026 he sold 7,579 shares at a weighted average price of $50.1142 per share, and on September 18, 2026 he sold 16,766 shares at a weighted average price of $50.7531, each sale executed in multiple trades within stated price ranges.

Heartflow, Inc. (HTFL) reported that its Chief Financial Officer, Vikram Verghese, sold a total of 34,975 shares of common stock in three open-market transactions on September 11, 14, and 15, 2026, at weighted average prices around $50 per share. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 4, 2026, and each trade was executed in multiple lots within the disclosed price ranges.

Heartflow, Inc. (HTFL) Chief Executive Officer and director John C.M. Farquhar reported the sale of a total of 38,900 shares of common stock in two open-market transactions on September 10 and 11, 2026. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025, including one trade executed in multiple transactions within a disclosed price range.

Heartflow, Inc. (HTFL) reported that its Chief Financial Officer, Vikram Verghese, sold 6,640 shares of common stock on September 8, 2026 in an open-market transaction at a weighted average price of $50.0319 per share, with trades executed between $50.00 and $50.12.

After this sale, he held 214,503 shares of Heartflow common stock directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 4, 2026.

Heartflow, Inc. (HTFL) disclosed that its Chief Financial Officer, Vikram Verghese, sold a total of 33,416 shares of common stock in open-market transactions on September 2–3, 2026. All reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 4, 2026.

On September 3, 2026, he sold 27,540 shares at a weighted average price of about $49.69 per share, from individual trades between $48.22 and $50.80. On September 2, 2026, he sold 5,876 shares at $50.60 per share in a separate open-market transaction.

Heartflow, Inc. (HTFL) reported that its Chief Executive Officer and director, John C.M. Farquhar, sold 27,230 shares of Common Stock on August 21, 2026 at a price of $50.00 per share in an open-market or private transaction. After this sale, he held 360,814 shares directly. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.

Heartflow, Inc. (HTFL) reported that Chief Executive Officer and director John C.M. Farquhar sold 32,676 shares of Common Stock in a sale transaction on August 18, 2026 at $45.00 per share, described as a sale in an open market or private transaction. After this transaction, he directly held 388,044 shares of Common Stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Farquhar on September 12, 2025.

Heartflow, Inc. (HTFL) reported that Chief Medical Officer Campbell Rogers exercised stock options for 9,219 shares of common stock at an exercise price of $19.00 per share and sold the same 9,219 shares at $41.23 per share on August 17, 2026. The option position had 82,972 options remaining after the exercise and continues to vest monthly until August 7, 2029, with an expiration date of August 7, 2035. These transactions were effected under a Rule 10b5-1 Trading Plan adopted on December 12, 2025. Rogers also reports indirect holdings of common stock through various trusts, including 22,615; 46,159; 26,012; and 50,754 shares, respectively.

Heartflow, Inc. (HTFL) reported that Chief Executive Officer John C.M. Farquhar sold 15,560 shares of common stock on August 14, 2026 at $39.06 per share in an open-market or private transaction. After this sale, he directly holds 420,720 shares of Heartflow common stock. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported a sale of 22,562 shares of Common Stock on 2026-08-10 at a price of $28.31 per share. Following this transaction, he directly holds 436,280 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.

Heartflow, Inc. Chief Accounting Officer Marie L. Jones reported several transactions in the company’s common stock. On March 6, 2026, she acquired 1,661 shares at $16.15 per share through an Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). On August 6 and 7, 2026, a total of 568 shares were withheld by the issuer at prices of $27.19 and $28.82 per share, respectively, to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units, rather than being sold in open-market transactions.

Heartflow, Inc. Chief Financial Officer Vikram Verghese reported several equity-related transactions in Heartflow common stock. On March 6, 2026, he acquired 671 shares at $16.15 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). On August 6, 2026, 1,537 shares and on August 7, 2026, 473 shares were withheld at $27.19 and $28.82 per share, respectively, to satisfy income tax withholding and remittance obligations related to the vesting and net settlement of previously reported restricted stock units. These tax-withholding events represent dispositions back to the issuer rather than open-market sales.

Heartflow, Inc. Chief Medical Officer Campbell Rogers reported two code F transactions in Common Stock, where an aggregate of 2,272 shares were retained by the issuer on August 6–7, 2026 to satisfy income tax withholding in connection with the vesting and net settlement of previously reported restricted stock units. Rogers also reports indirect ownership of Common Stock through several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust and other trust holdings.

Heartflow, Inc. director and Chief Executive Officer John C.M. Farquhar reported two Form 4 transactions involving Common Stock. On August 6 and 7, 2026, a total of 7,751 shares were disposed of under code F at prices of $27.19 and $28.82 per share. According to the disclosure, these shares were retained by the issuer to satisfy income tax withholding and remittance obligations related to the vesting and net settlement of previously reported restricted stock units, rather than discretionary open-market sales.

Heartflow, Inc. reported that Chief Executive Officer John C.M. Farquhar exercised stock options covering 31,220 shares of common stock on 2026-07-30. The options converted at exercise prices of $2.22, $8.33 and $9.58 per share. Footnotes describe vesting schedules with monthly installments continuing until July 1, 2027 and November 12, 2028 for certain grants, while another grant is already fully exercisable.

Heartflow, Inc. Chief Financial Officer Vikram Verghese exercised stock options for 22,522 shares of common stock on July 27, 2026 at $2.22 per share. He now holds 255,898 common shares directly and 66,588 stock options that vest monthly until October 30, 2027 and expire on December 24, 2033.

Heartflow, Inc. director Jeffrey C. Lightcap exercised stock options covering 47,420 shares of common stock on July 24, 2026 at an exercise price of $19.00 per share. Following the exercise, his directly held common stock position increased to 293,681 shares, and the reported option grant was fully exhausted.

Affiliated investment entities report additional Heartflow common stock holdings: 4,615,542 shares by HCPCIV 1, LLC, 833,075 shares by HealthCor Partners Fund II, L.P., and 1,248,939 shares by HealthCor Partners Fund, L.P. Lightcap may be deemed to share voting and dispositive power over these securities but disclaims beneficial ownership beyond his pecuniary interest.

Heartflow, Inc. director Timothy C. Barabe exercised 3,710 stock options for Heartflow common stock on July 22, 2026 at an exercise price of $19.00 per share. The exercise converted the options into 3,710 shares of common stock, leaving him with 15,000 stock options and 188,231 common shares held directly.

Heartflow, Inc. reports that Chief Financial Officer Vikram Verghese exercised stock options for 22,522 shares of common stock at $2.22 per share on 2026-07-21. The stock option position decreased to 89,110 options, while his directly held common stock increased to 233,376 shares. The option vests in monthly installments through October 30, 2027, subject to continued service.

Heartflow, Inc. director Timothy C. Barabe exercised stock options covering 5,000 shares of common stock on July 17, 2026 at an exercise price of $19.00 per share. Following the option exercise, he directly owned 184,521 common shares and held 18,710 stock options, which are fully exercisable.

Heartflow Chief Medical Officer Campbell Rogers exercised 9,219 stock options at an exercise price of $19.00 per share into common stock on July 15, 2026, and on the same day sold 9,219 common shares at $25.72 per share pursuant to a Rule 10b5-1 Trading Plan adopted on December 12, 2025.

After these transactions, he held 88,731 Heartflow common shares directly and 92,191 stock options, and also had indirect common stock holdings through trusts, including 50,754, 26,012, 46,159 and 22,615 shares held by various Rogers family trusts.

Heartflow, Inc. Chief Executive Officer and director Farquhar John C.M. reported an open-market sale of 22,562 shares of Common Stock on July 10, 2026 at a price of $27.75 per share. Following the transaction, he holds 435,373 shares directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.

Heartflow, Inc. director William C. Weldon exercised stock options to acquire 51,369 shares of Common Stock on 2026-07-08 through three derivative exercises. Each exercise covered 17,123 underlying shares at an exercise price of 8.3300 per share. Following these transactions, he holds 243,931 shares of Common Stock directly, with the exercised stock options now fully used.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of common stock. On June 24, 2026, he sold 38,900 shares at $35.00 per share in a transaction executed under a Rule 10b5-1 trading plan adopted on September 12, 2025.

Following the sale, Farquhar directly held 457,935 shares of Heartflow common stock. The sale amounts to roughly 8% of his post-transaction holdings, suggesting a moderate, pre-planned reduction rather than a large change in his overall equity position.

Heartflow, Inc. director William C. Weldon received a new stock option grant. The award covers 16,075 stock options for Heartflow common stock at an exercise price of $32.05 per share, giving him the right to buy shares at that price in the future.

The option vests in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders or the first anniversary of the grant date, subject to his continued service. After this grant, he holds 16,075 options directly, and the option is scheduled to expire on June 16, 2036.

Heartflow, Inc. director Timothy C. Barabe received a grant of stock options as part of his compensation. He was awarded options to purchase 16,075 shares of Heartflow common stock at an exercise price of $32.05 per share, expiring on June 16, 2036. Following this grant, he holds 16,075 stock options directly. According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders or the first anniversary of the grant date, subject to his continued service.

Heartflow, Inc. reported that director Julie A. Cullivan received a grant of stock options covering 16,075 shares of common stock. The options have an exercise price of $32.05 per share and expire on June 16, 2036.

According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 or the first anniversary of the grant date, subject to her continued service through that date. This filing reflects a compensation-related award, with no share sales reported.

Heartflow, Inc. director Jeffrey C. Lightcap received a grant of stock options covering 16,075 shares of common stock. The options have an exercise price of $32.05 per share and expire on June 16, 2036.

According to the grant terms, the option will vest in full on the earlier of the day prior to Heartflow’s annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to Mr. Lightcap’s continued service through that date. Following this grant, he holds options for 16,075 underlying shares directly.

Heartflow, Inc. director Riley Wayne Joseph reported receiving a stock option grant as part of his compensation. The award covers 16,075 shares of common stock at an exercise price of $32.05 per share, with the option expiring on June 16, 2036.

The filing shows this is a grant/award acquisition rather than an open-market trade. According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's 2027 annual shareholder meeting or the first anniversary of the grant date, subject to his continued service.

Heartflow, Inc. director Casey M. Tansey reported a grant of stock options. On the reported date, Tansey received options covering 16,075 shares of Common Stock at an exercise price of $32.05 per share. Following this grant, Tansey held 16,075 derivative securities directly.

The option will vest in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders and the first anniversary of the grant date, subject to continued service through that date. The options are scheduled to expire on June 16, 2036 if not exercised.

Heartflow, Inc. Chief Medical Officer Campbell Rogers reported an exercise of stock options into common shares. He exercised 10,000 stock options at an exercise price of $2.22 per share, receiving 10,000 shares of Heartflow common stock.

The filing shows Rogers holding 88,731 common shares directly after the transaction, plus additional indirect holdings in several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust. Following the exercise, he also retains 71,633 stock options directly. The option exercise was carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 12, 2025.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of 22,562 shares of common stock at $28.50 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 496,835 shares directly, indicating a relatively small portion of his stake was sold.

Heartflow, Inc. Chief Medical Officer Campbell Rogers reported an option exercise and related share sale in Common Stock. On May 18, 2026, he exercised stock options to acquire 9,219 shares at $19.00 per share, then sold 9,219 shares in an open-market transaction at $28.34 per share.

The filing shows he now holds 78,731 Common Stock shares directly. In addition, multiple trusts associated with him and his spouse report indirect holdings, including 50,754 shares by The Campbell Rogers Revocable Trust and 26,012 shares by a spouse’s trust. The footnotes state the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 12, 2025.

Heartflow, Inc. director and Chief Executive Officer John C.M. Farquhar sold 22,562 shares of Common Stock in an open-market transaction at $29.12 per share on May 11, 2026. Following this sale, he directly holds 519,397 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.

Heartflow, Inc.’s Chief Accounting Officer, Marie L. Jones, reported routine tax-related share dispositions. On two dates, a total of 567 shares of Common Stock were retained by Heartflow to satisfy income tax withholding tied to vesting of previously reported restricted stock units.

These Form 4 entries reflect tax-withholding dispositions rather than open-market sales, so they do not indicate active trading decisions. After these transactions, Jones directly holds 31,083 shares of Heartflow common stock.

Heartflow, Inc. Chief Medical Officer Campbell Rogers reported routine tax-related share dispositions, not open-market sales. On May 6, 1,634 shares of common stock were withheld at $30.29 per share to cover income tax obligations tied to vesting restricted stock units. On May 7, an additional 637 shares were withheld at $29.98 per share for the same purpose. After these transactions, Rogers directly held 78,731 shares of Heartflow common stock. The filing also shows indirect holdings through multiple trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust, 26,012 shares by a spouse's trust, 46,159 shares by the CR Asset Protection Trust of 2023, and 22,615 shares by the Campbell Rogers 2019 Irrevocable Trust.

Heartflow, Inc. Chief Financial Officer Vikram Verghese reported routine share dispositions related to tax withholding on vesting restricted stock units. On May 6, the issuer retained 1,536 shares of common stock at $30.29 per share, and on May 7 retained 473 shares at $29.98 per share. These 2,009 shares were withheld by the company to satisfy income tax obligations, not sold in the open market, and Verghese held 210,854 shares directly following the most recent transaction.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported routine tax-withholding share dispositions tied to restricted stock unit vesting. On May 6, 5,300 shares of common stock were withheld at $30.29 per share, and on May 7, 1,904 shares were withheld at $29.98 per share.

According to the footnote, these shares were retained by Heartflow to satisfy income tax withholding and remittance obligations in connection with previously reported RSU vesting and net settlement, rather than sold in the open market. Following these transactions, Farquhar directly holds 541,959 shares of Heartflow common stock.

Heartflow, Inc. disclosed that investment entities affiliated with Bain Capital Life Sciences, including BCLS Fund III Investments, LP, reported open-market sales of a combined 2,000,000 shares of Common Stock. The sales occurred on April 28–30, 2026 at weighted average prices generally between $29.00 and $31.46 per share.

The securities are held directly by BCLS Fund III Investments, LP, while related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power and each disclaims beneficial ownership except to the extent of its pecuniary interest. After these transactions, the filing shows indirect holdings of up to 10,194,048 shares on the earliest reported date and 8,448,158 shares following the latest reported sale.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of 22,562 shares of Common Stock at $26.72 per share on April 10, 2026. After this trade, he directly holds 549,163 shares, indicating he retained the vast majority of his position.

The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, suggesting the transaction was scheduled in advance as part of a systematic trading program rather than a spur-of-the-moment decision.

Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. On April 1, 2026, he exercised options covering 67,017 shares of common stock at exercise prices of $2.22 and $8.33 per share and received the same number of common shares.

That day, he sold 64,533 shares of common stock at a weighted average price of $24.64 per share in open-market transactions, as part of a Rule 10b5-1 Trading Plan adopted on September 12, 2025. Following these transactions, he holds 81,002 shares directly, along with indirect holdings through several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust.

Heartflow, Inc. director Jeffrey C. Lightcap reported an internal restructuring of his share ownership. On March 24, 2026, HCPCIV 1, LLC made a pro rata in-kind distribution of Heartflow common stock to its members, including 206,261 shares allocable to Mr. Lightcap based on his indirect interest. Following this distribution and the dissolution of HCPCIV, these shares are now held directly by Mr. Lightcap, with 246,261 shares shown as directly owned after the transaction. He is also a controlling member of HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P., which report 833,075 and 1,248,939 shares held indirectly, respectively, although he disclaims beneficial ownership beyond his pecuniary interest.

Heartflow, Inc. insider HealthCor Partners Management LP reported a restructuring-type transaction involving 4,615,542 shares of Heartflow common stock. On March 24, 2026, these shares, held indirectly through HCPCIV I, LLC, were distributed to fund investors, and the reporting person’s indirect holdings in this block dropped to zero. This was classified as an “other” transaction rather than an open-market purchase or sale.

Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. He exercised options covering 67,017 shares of common stock at an exercise price of $2.22 per share, then sold 64,533 shares at a weighted average price of $25.6928 per share in trades ranging from $25.00 to $28.00.

The option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025. Following these transactions, Rogers holds 78,518 shares of Heartflow common stock directly, along with additional indirect holdings through several trusts, including 22,615 shares held by the Campbell Rogers 2019 Irrevocable Trust.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar sold 9,725 shares of Common Stock in an open-market transaction at $25.00 per share on March 18, 2026. After this sale, he directly holds 571,725 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Heartflow, Inc. director Timothy C. Barabe exercised stock options and acquired 8,667 shares of common stock on March 11, 2026 at $2.22 per share. Following the transaction, he directly owns 179,521 common shares. The option grant continues to vest in monthly installments through July 1, 2027, subject to his continued service.

Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported mixed share activity. He sold 12,837 shares of common stock in an open-market transaction at $22.66 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Earlier, he acquired 2,631 shares at $16.15 per share as a grant under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). After these transactions, he directly holds 581,450 shares of Heartflow common stock.

Heartflow, Inc. director Julie A. Cullivan reported an open-market sale of 9,122 shares of common stock at $25.00 per share on March 5, 2026. After this transaction, she held 27,291 shares directly. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated September 12, 2025.

Heartflow, Inc. director Timothy C. Barabe reported exercising stock options for 2,497 shares of common stock on February 17, 2026. The options were converted into common shares at $8.33 per share, increasing his directly held stake to 170,854 common shares. This was an option exercise (code M), not an open-market purchase.